Skip to main content

JR in the Pharmaceuticals Sector: An Update

Buy Article:

$37.09 plus tax (Refund Policy)


An earlier article outlined the application of judicial review in the pharmaceuticals sector.1 As noted there, judicial review has become an ever-increasingly important feature of the law in this sector, and most such reviews have taken place at the instance of third parties rather than those directly the subject of the decision. In the short period of time since that article there have been a number of further developments, which this article seeks to summarise.

Keywords: Directive 65/65/EEC; Medicines Act 1968; judicial review; parallel imports; pharmaceutical sector; “Ten Year” Rule

Document Type: Research Article

Publication date: June 1, 1998

More about this publication?
  • Judicial Review is now firmly established as the UK's leading journal for lawyers engaged in judicial review, catering for both practitioners and academics. It offers invaluable insights from today's foremost judicial review experts, combining analysis of general judicial review matters with practical information and guidelines for use by practitioners in the prepartation and conduct of applications for judicial review. The journal includes short and accessible items on the law, practice and procedure and recent cases. There is coverage of sub-topics within judicial review such as constitutional change, prison cases, commercial, and environmental judicial review. Other popular features are reviews of the academic literature, surveys of the leading cases, case commentaries and summaries of recent research.


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more